Tag: InvaGen Pharmaceuticals
InvaGen to acquire Avenue Therapeutics for specialty hospital business in the...
At the first stage closing, InvaGen or its affiliates will acquire, through the issuance by Avenue of new shares, shares representing a 33.3% stake in Avenue’s capital stock on a fully diluted basis for $35 million...…………...